Zhongqi Zhang

Dr. Zhongqi Zhang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2022 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
YXYafei Xu
Yafei Xu
YZYuling Zheng
Yuling Zheng
TTTianying Tang
Tianying Tang
LCLvlv Chen
Lvlv Chen
YZYiwen Zhang
Yiwen Zhang
ZZZhongqi Zhang
Zhongqi Zhang

20 September 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YZYuling Zheng
Yuling Zheng
YXYafei Xu
Yafei Xu
BHBixin Huang
Bixin Huang
YMYing Mai
Ying Mai
YZYiwen Zhang
Yiwen Zhang
ZZZhongqi Zhang
Zhongqi Zhang
Objective: This study aimed to determine the optimal dose of propofol combined with esketamine to inhibit the response to gastroscope insertion in elderly patients.Methods: This is a prospective, non-controlled, non-randomized, single-center study. Elderly patients aged 65–80 years were enrolled in the study with the American society of anesthesiologists (ASA) physical status I or II undergoing elective gastroscopy. All patients were administered propofol after an intravenous esketamine at the dosage of 0.3 mg/kg 30 s, the subsequent dose of propofol was determined by the response of the previous patient to gastroscope insertion (choking, body movement, etc.) using Dixon’s up-and-down method. The initial dose of propofol administered to the first elderly patient was 3.0 mg/kg, and the standard ratio of propofol dose in adjacent patients was 0.9. At least six crossover points were obtained before the conclusion of the study. By using Probit analysis the median effective dose (ED50), 95% effective dose (ED95), and the corresponding 95% confidence interval (CI) for propofol were determined.Results: The study continued until we obtained seven crossover points and 32 elderly patients (17 males and 15 females) were collected. The ED50 of propofol combined with esketamine inhibiting response to gastroscope insertion in elderly patients were found to be 1.479 mg/kg (95% CI 1.331–1.592 mg/kg), and ED95 was found to be 1.738 mg/kg (95% CI 1.614–2.487 mg/kg).Conclusion: According to the present study, propofol combined with 0.3 mg/kg esketamine is safe and effective for elderly patients undergoing gastroscopy. The ED50 and ED95 doses of propofol inhibiting response to gastroscope insertion in elderly patients when combined with 0.3 mg/kg esketamine were 1.479 and 1.738 mg/kg, respectively, without apparent adverse effects.

1 May 2020 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Open access
YZYiwen Zhang
Yiwen Zhang
XZXiaoxia Zhang
Xiaoxia Zhang
ZXZumin Xing
Zumin Xing
STShuyi Tang
Shuyi Tang
HCHanwen Chen
Hanwen Chen
YLYalan Li
Yalan Li
Bone cancer pain (BCP) is a common chronic pain that is caused by a primary or metastatic bone tumor. More detailed molecular mechanisms of BCP are warranted. In this study, we established a BCP rat model. The von Frey hair test, body weight, and hematoxylin and eosin staining were employed. We screened differentially expressed circRNAs (DECs) between the BCP group and sham group. The results revealed that 850 DECs were significantly up-regulated and 644 DECs were significantly down-regulated in the BCP group. Furthermore, we identified 1177 differentially expressed genes (DEGs) significantly up-regulated and 565 DEGs significantly down-regulated in the BCP group. Gene Ontology annotation of all 1742 DEGs revealed that biological regulation of metabolic processes, cellular processes, and binding were the top enriched terms. For Kyoto Encyclopedia of Genes and Genomes analysis, phagosome, HTLV-I infection, proteoglycans in cancer, and herpes simplex infection were significantly enriched in this study. In addition, we identified four selected circRNAs, chr6:72418120|72430205, chr20:7561057|7573740, chr18:69943105|69944476, and chr5:167516581|167558250, by quantitative real time PCR. chr6:72418120|72430205 (circStrn3) was selected for further study based on expression level and the circRNA-miRNA-mRNA network table. Western blot analysis suggested that knockdown of circStrn3 could effectively induce Walker 256 cell apoptosis. In summary, our study provided a more in-depth understanding of the molecular mechanisms of BCP.

12 June 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
STShuyi Tang
Shuyi Tang
YZYuling Zheng
Yuling Zheng
XLXiaoli Li
Xiaoli Li
YZYiwen Zhang
Yiwen Zhang
ZZZhongqi Zhang
Zhongqi Zhang
Objective: Propofol and etomidate are the most commonly used sedative agents in procedural sedation, each with its own advantages and disadvantages. However, there remains considerable controversy regarding the optimal ratio for the mixture of these two drugs, warranting further investigation. Therefore, this study aims to investigate the optimal ratio for combining propofol and etomidate during gastroscopy.Methods: This study is a prospective, double-blinded, randomized controlled clinical trial. One hundred and sixty-two patients from July 2019 to December 2022 were evenly classified into three groups using a random number table as follows: (1) P group (propofol); (2) EP1 group (5 mL etomidate +10 mL propofol); (3) EP2 group (10 mL etomidate +10 mL), 54 patients per group. The medications, including a pre-sedation dose of 50 μg/kg dezocine followed by sedatives, ceasing when the patient’s eyelash reflex vanished, indicating adequate sedation. Mean arterial pressure (MAP), heart rate (HR), and peripheral oxygen saturation (SpO2) measurements taken before anesthesia (T1), immediately after the administration of sedatives (T2), immediately gastroscopic insertion (T3) and immediately recovery (T4) were determined. Additional, perioperative related outcomes and adverse events were also recorded.Results: The EP2 group exhibited a higher MAP at T2 compared to the P and EP1 groups (p < 0.05). Calculated decreases in MAP revealed values of 19.1, 18.8, and 13.8% for the P, EP1, and EP2 groups at T2, respectively. Adverse events: Group EP2 exhibited a significantly lower hypotension incidence (11.1%) compared to the Propofol group (50%) and EP1 (31.5%). Concerning injection pain, Group EP2 also showing a significant decrease in comparison to P and EP1 groups (p < 0.05).Conclusion: The use of a mixture of 10 mL etomidate and 10 mL propofol (at a 1:1 ratio) combined with dezocine for painless gastroscopy demonstrates hemodynamic stability, a low incidence of adverse reactions.Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=39874

1 January 2024 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
BHBixin Huang
Bixin Huang
XLXiaoling Li
Xiaoling Li
YZYuling Zheng
Yuling Zheng
YMYing Mai
Ying Mai
ZZZhongqi Zhang
Zhongqi Zhang
The present study utilized the spared nerve injury (SNI) to create a mouse model of depression to investigate the impact of esketamine on depressive-like behaviors, on the expression of PSD-95 and CRMP2 proteins, and on changes in neuronal dendritic spine plasticity in the prefrontal cortex (PFC). Depressive-like behavioral tests were performed 1 h after esketamine treatment, and the PFC tissues were obtained on the fourth day after completing the behavioral tests. Then, dendritic spine density and morphology in the PFC were measured using Golgi staining, and CRMP2 and PSD-95 proteins were obtained from PFC tissue by western blotting. The results of this study showed that esketamine significantly increased the immobility time in the forced swimming test and tail suspension test. In the open field test, esketamine increased the time spent in the open arms, the time spent in the central area, and the total distance covered. It also increased the protein expression levels of CRMP2 and PSD-95 in addition to the total and mature dendritic spine density of the PFC in SNI-depressed mice. Esketamine can significantly improve depression-like behaviors in SNI-depressed mice and promote an increase in dendritic spine density and maturation in the PFC. These effects may be associated with changes in CRMP2 and PSD-95 expression.

18 March 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JCJinming Chen
Jinming Chen
YMYing Mai
Ying Mai
XCXiaolei Cheng
Xiaolei Cheng
HSHao Sun
Hao Sun
ZCZhihong Chen
Zhihong Chen
ZZZhongqi Zhang
Zhongqi Zhang
Introduction: The combination of remimazolam and esketamine effectively alleviates adverse hemodynamic effects, such as tachycardia and hypertension, during intubation. However, the dosage for achieving optimal intubation conditions when co-administered with remifentanil remains unestablished. Therefore, this study aimed to determine the effective doses of remimazolam and esketamine for endotracheal intubation without muscle relaxants in pediatric patients using Dixon’s up-and-down method.Methods: This prospective, non-controlled, non-randomized clinical trial sequentially allocated 41 children aged 3–6 into two phases. All patients underwent tracheal intubation under general anesthesia. Patients received a fixed dose of remifentanil at 2.5 μg/kg via a pump over 90 s. In the first phase, the induction dose of remimazolam was set at 0.2 mg/kg. The first patient received esketamine at a dose of 0.5 mg/kg, administered with a dose gradient of 0.2 mg/kg based on Dixon’s up-and-down method. 50% effective dose (ED50) and 95% effective dose (ED95) for esketamine were then measured through probit regression analysis. Similarly, in the second phase, the ED95 of esketamine was fixed. The first patient received remimazolam at a dose of 0.2 mg/kg, administered at a dose gradient of 0.1 mg/kg. ED50 and ED95 for remimazolam were then measured. Intubation conditions were assessed via the Copenhagen scale. Heart rate (HR) and mean arterial pressure (MAP) were recorded at the following time points: Just before intubation (T1) and 1 min after intubation (T2). Adverse events were also recorded during anesthesia induction.Results: At a fixed dose of remifentanil (2.5 μg/kg), the ED50 of esketamine was 0.74 mg/kg (95% confidence interval [CI]: 0.61–0.89 mg/kg), while the ED95 was 0.97 mg/kg (95% CI: 0.85–1.75 mg/kg). The ED50 of remimazolam was 0.39 mg/kg (95% CI: 0.29–0.53 mg/kg), while the ED95 was 0.56 mg/kg (95% CI: 0.46–1.47 mg/kg). Hemodynamic stability was maintained during anesthesia induction, with no significant adverse events observed.Conclusion: The ED50 and ED95 values of remimazolam and esketamine in this study provide initial dosing references for pediatric endotracheal intubation without muscle relaxants. A fixed dose of 2.5 μg/kg remifentanil combined with these agents is safe and effective in children aged 3–6 years, though further multicenter studies are recommended for validation.Clinical trial registration: www.chictr.org.cn, number: ChiCTR2200063847.